title: Profound alterations of the lipoprotein metabolism during danazol treatment in premenopausal women.
abstract: Twelve women with pelvic endometriosis were treated with 600 mg of danazol daily for 24 weeks. The molar and fractional lecithin:cholesterol acyl transfer (LCAT) rates and the concentrations of cholesterol, phospholipids, and triglycerides were determined in plasma and in the very low-density lipoprotein, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and HDL2 and HDL3 fractions before, during, and after the medication. After 2 weeks the HDL, HDL2, and HDL3 cholesterol concentrations were reduced by 49%, 73%, and 29%, respectively, while the LDL level was increased by 14%. The molar and fractional LCAT rates decreased during treatment, and these reduced LCAT rates are consistent with a reduced fractional LDL removal. Within 8 weeks after cessation of medication, all parameters had returned to the pretreatment levels.
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood; D003613:Danazol / Q000494:pharmacology* / Q000627:therapeutic use; D004715:Endometriosis / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D010386:Pelvic Neoplasms / Q000097:blood* / Q000188:drug therapy; D010743:Phospholipids / Q000097:blood; D011245:Pregnadienes / Q000494:pharmacology*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D011245:Pregnadienes; D014280:Triglycerides; D002784:Cholesterol; D003613:Danazol